Study: NCT00353652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study #1: spironolactone (SP), titrated dose
Description: Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study #1: spironolactone (SP), titrated dose
Description: Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 chlorthalidone (CTD), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 chlorthalidone (CTD), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 chlorthalidone (CTD), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 chlorthalidone (CTD), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 chlorthalidone (CTD), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 chlorthalidone (CTD), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 spironolactone (SP), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 spironolactone (SP), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 spironolactone (SP), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 spironolactone (SP), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 spironolactone (SP), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 spironolactone (SP), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 irbsesartan (IR), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.